Clinical Outcomes of Short- Versus Long-Course Antibiotic Therapy in Pseudomonas aeruginosa-Positive Mild-to-Moderate Bronchiectasis Stratified by Day-7 Sputum Bacterial Load
This retrospective cohort study suggests that in patients with mild-to-moderate *Pseudomonas aeruginosa*-positive bronchiectasis, a low day-7 sputum bacterial load (≤ 10⁶ CFU/mL) identifies a subgroup where short-course (≤ 7 days) antibiotic therapy yields comparable rehospitalization rates to long-course treatment while being associated with better long-term pulmonary function and quality of life.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the lungs as a complex network of airways that, in a healthy person, stay clear and flexible. For some people, however, these airways become permanently widened and scarred, a condition known as bronchiectasis. This damage creates pockets where mucus pools, becoming a breeding ground for bacteria. When these bacteria multiply, they trigger sudden flare-ups called acute exacerbations, marked by increased coughing, more sputum, and a feeling of breathlessness. One particularly stubborn bacterium, Pseudomonas aeruginosa, often takes up residence in these damaged lungs. It is notorious for causing more frequent flare-ups and a faster decline in lung function. The medical challenge lies in knowing how long to treat these infections with antibiotics. While standard guidelines often suggest a two-week course, doctors have long wondered if this fixed duration is necessary for everyone, or if it might be too long for some patients, exposing them to unnecessary side effects and the risk of creating drug-resistant bacteria.
A team of researchers at Jiaxing University in China set out to explore whether the amount of bacteria present in a patient's sputum after one week of treatment could help decide when to stop the antibiotics. They focused on patients with mild-to-moderate bronchiectasis who were hospitalized for a flare-up involving Pseudomonas. Instead of assigning patients to different treatment lengths by chance, the researchers looked back at the medical records of 102 patients treated in 2022. They grouped these patients based on what actually happened in the hospital: those who received antibiotics for seven days or fewer, and those who received them for more than seven days. Crucially, on the seventh day of treatment, every patient had their sputum tested to count exactly how many bacteria remained. The doctors had then decided whether to stop the medication or continue based on how the patient felt and what the bacterial count showed.
The researchers followed these patients for a full year after they left the hospital to see how they fared. They tracked whether patients had to be readmitted to the hospital, how often they needed antibiotics again, and how their lung function and overall quality of life changed. The data revealed a clear pattern linked to the bacterial count on day seven. Patients who still had a high number of bacteria in their sputum after a week were much more likely to have severe disease and required longer courses of antibiotics. In contrast, a specific group of patients had managed to lower their bacterial count to a very low level by day seven. For these individuals, stopping treatment early did not lead to worse outcomes. In fact, the patients who stopped after seven days had similar rates of hospital readmission and similar times before needing antibiotics again as those who took the longer course.
What was perhaps more surprising was that the group who stopped treatment early actually did better in other ways. A year later, they had better lung function and reported a higher quality of life compared to the group that took antibiotics for longer. This difference remained even after the researchers adjusted for the fact that the two groups started with slightly different health levels. The study suggests that for patients with mild-to-moderate bronchiectasis who have successfully reduced their bacterial load to a low level within the first week, continuing antibiotics for a full two weeks may offer no extra benefit and could potentially be associated with poorer long-term lung health. The findings point toward a more personalized approach, where the decision to stop treatment is guided by a specific measurement of bacteria rather than a fixed calendar date. However, the authors note that because this was a retrospective look at past records rather than a new experiment where patients were randomly assigned to groups, these results are a strong suggestion for future study rather than a final proof. The work provides a compelling reason to test this idea in a new, controlled trial to see if measuring bacteria on day seven can safely become a standard tool for deciding antibiotic duration.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.